Natalizumab

Novel agents to control seizures & target epileptogenesis 1:28
Novel agents to control seizures & target epileptogenesis
Claude Steriade • 24 Mar 2022
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs 3:15
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs
Virginia Meca-Lallana • 28 Feb 2022
Autoreactive T-cell responses in multiple sclerosis: unanswered questions 2:14
Autoreactive T-cell responses in multiple sclerosis: unanswered questions
Olivia Thomas • 21 Oct 2021
Characterizing the autoantigen-specific T-cell repertoire in MS 6:29
Characterizing the autoantigen-specific T-cell repertoire in MS
Olivia Thomas • 21 Oct 2021
Comparing exit strategies in natalizumab-responders at high risk for PML 7:33
Comparing exit strategies in natalizumab-responders at high risk for PML
Emanuele D'Amico • 30 Sep 2021
Discovering markers of disease progression in patients with MS treated with natalizumab 2:08
Discovering markers of disease progression in patients with MS treated with natalizumab
Charlotte Teunissen • 6 Oct 2021
COVID-19 cases in MS patients receiving IV therapy 1:49
COVID-19 cases in MS patients receiving IV therapy
Celia Oreja-Guevara • 14 Oct 2021
Humoral response to COVID-19 vaccination in patients with MS 6:28
Humoral response to COVID-19 vaccination in patients with MS
Celia Oreja-Guevara • 14 Oct 2021
Long-term efficacy outcomes of natalizumab vs. fingolimod in highly active RRMS 3:30
Long-term efficacy outcomes of natalizumab vs. fingolimod in highly active RRMS
Nikolaos Grigoriadis • 20 Sep 2021
BBB permeability changes predict treatment response to alemtuzumab in RRMS 5:26
BBB permeability changes predict treatment response to alemtuzumab in RRMS
Maria Højberg Knudsen • 1 Oct 2021
The future of biomarkers in MS: novel discoveries and defining protocols 2:12
The future of biomarkers in MS: novel discoveries and defining protocols
Charlotte Teunissen • 6 Oct 2021
Real-world comparison of natalizumab exit strategies in patients with RRMS 9:25
Real-world comparison of natalizumab exit strategies in patients with RRMS
Aurora Zanghì • 22 Jun 2021
Benefits of SC natalizumab in MS 2:43
Benefits of SC natalizumab in MS
Bart Van Wijmeersch • 23 Jun 2021
Enhancing convenience and flexibility with SC natalizumab for MS 2:19
Enhancing convenience and flexibility with SC natalizumab for MS
Bart Van Wijmeersch • 23 Jun 2021
NfL to monitor treatment effects in MS 3:26
NfL to monitor treatment effects in MS
Charlotte Teunissen • 4 Jun 2021
Novel biomarkers to predict progression in MS 4:28
Novel biomarkers to predict progression in MS
Charlotte Teunissen • 4 Jun 2021
The content of VJNeurology is intended for healthcare professionals